Navigation Links
QRxPharma to Sponsor Symposium at 13th World Congress on Pain Meeting
Date:8/31/2010

SYDNEY and BEDMINSTER, N.J., Aug. 31 /PRNewswire/ -- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today it will sponsor a symposium at the 13th World Congress of Pain on 31 August, 2010 at Palais des congres de Montreal.  The symposium, titled "Dual Opioid Therapy: Changing the Paradigm" will focus on preclinical and clinical data for MoxDuo®IR, an immediate-release Dual Opioid product for moderate to severe acute pain.  Featured speakers who will highlight Dual Opioids at this symposium are internationally recognised pain experts, Drs. Nicholson, Pasternak and Webster.

In addition to the symposium, QRxPharma was invited to present three posters on September 2, from 9:30-10:30 with the results from MoxDuo IR comparative trials:

  • "Morphine Equivalent Doses of Dual Opioid Treatment With Morphine Plus Oxycodone Versus Morphine and Oxycodone Monotherapy for Post-Operative Pain: Safety and Analgesic Profiles"
  • "Treatment of Post-Operative Pain With a Dual Opioid Combination of Morphine and Oxycodone: Analgesia and Side Effects"
  • "An Active Controlled Evaluation of the Efficacy and Safety of Dual Opioid Treatment With Morphine Plus Oxycodone for Acute Pain Following Total Knee Arthroplasty"

In the recently completed Phase 3 Combination Rule Study, MoxDuo IR demonstrated both a statistically superior analgesic effect compared to morphine and oxycodone alone as well as a favourable side effect profile despite delivering twice the opioid dose of its individual components.  The Company is currently completing its final Phase 3 registration trial for MoxDuo IR in patients who have undergone total knee replacement surgery.

When compared to other opioids at equi-analgesic doses, MoxDuo IR reduced the occurrence rate and intensity of moderate to severe nausea, vomiting and dizziness by 50-75% or more (study 021) and demonstrated when such Adverse Events (AEs) do occu
'/>"/>

SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... ORLANDO, Fla. , May 18, 2013 ... and are considered the most sensitive method for ... completely effective in preventing cancer cases 3 . EndoChoice ... its new Fuse™ system significantly improves the accuracy of ... missed by colonoscopists. EndoChoice will be discussing these clinical ...
(Date:5/18/2013)... May 18, 2013 The Open Paradigm ... Occupy Psychiatry , and leading organizations ... announces a social media campaign showcasing video testimonials ... model, which focuses on pathology and illness rather ... the American Psychiatric Association,s (APA) rollout of its ...
(Date:5/18/2013)... 2013 Faruqi & Faruqi, LLP, a ... securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" or ... http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation focuses ... federal securities laws by issuing materially false and/or ... trials for Tivopath (tivozanib) (titled "TIVO-1").  Specifically, the ...
Breaking Medicine Technology:New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
... Dec. 23 BioTrends Research Group, Inc. published ... in the United States," based on ... clinical practice. The report evaluates patient types, ... Hematologists, Oncologists, Nephrologists, Gastroenterologists, OB-GYNs, Rheumatologists, Cardiologists and ...
... , , , PARIS, December ... discovery and development of novel antibiotics,designed to overcome the ... its shareholders have signed a definitive,agreement whereby Novexel shall ... up to $505 million, including contingent payments and the,net ...
Cached Medicine Technology:BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties 2Novexel to be Acquired by AstraZeneca 2Novexel to be Acquired by AstraZeneca 3Novexel to be Acquired by AstraZeneca 4
(Date:5/18/2013)... Utah (PRWEB) May 18, 2013 ... on insurance agents’ role in Marketplaces . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... Health and Human Services (HHS) recently released a ...
(Date:5/18/2013)... May 18, 2013 The Communities of ... special places we call home. These are the townships, villages ... are the locations where the people are friendly and neighbors ... viewers off the highways and shares the best in both ... nations with an American sports and film celebrity. It airs ...
(Date:5/18/2013)... “World Healthcare IT Market: Trends & Forecast (2010 – ... and opportunities in North America, Europe, Asia, & Rest ... 89 market data tables , 20 ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers will ... IT market is expected to grow from $99.6 billion ...
(Date:5/18/2013)... FL (PRWEB) May 18, 2013 TheBeautyPlace.com ... Nioxin. Pattern hair loss is not a result of ... According to Men’s Fitness Magazine, 70% of men suffer ... Professional Strength is renowned for hair transplant surgery, ... fights male pattern baldness known as Bosley Professional Strength. ...
(Date:5/18/2013)... New York, New York (PRWEB) May 18, 2013 ... continue to mount in courts throughout the country, Bernstein ... that metal-on-metal hip replacement patients often suffer tissue damage ... During the study, which according to Science Daily will ... 69 metal-on-metal hip replacement recipients underwent MRI screens of ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4
... every patient in Sweden having percutaneous coronary intervention ... coronary artery disease- has found that PCI implantations ... associated with lower rates of relapse (restenosis), stent ... stents and bare-metal stents.(1) The findings, from ...
... diagnosed with diabetes and hypertension have time to try ... without medications, but not too much time. ... to a year were smalla two-day reduction in quality-adjusted ... researchers published online for the Journal of General ...
... (HealthDay News) -- Inflammatory bowel disease (IBD) is becoming more ... Researchers who analyzed data from all population-based studies about the ... new cases is increasing or stable in virtually every region ... had the highest number of cases, while Asia had a ...
... There,s new evidence that annual prostate cancer screening does not ... 50s and 60s and those with underlying health conditions, according ... in St. Louis. A longer follow-up of more than ... years of aggressive, annual screening for prostate cancer led to ...
... doesn,t affect the quantity (or value) of imaging services received ... study in the January issue of the Journal of ... 51 million Americans, or 16.7 percent of the population, were ... of insurance is associated with less preventive care, delays in ...
... By Alan Mozes HealthDay Reporter , FRIDAY, Jan. ... to different people -- for some, anxiety and paranoia can ... a unique brain scan study suggests two ingredients in pot ... who watched the effects of the two marijuana ingredients -- ...
Cached Medicine News:Health News:New 'real-world' reassuring data from the SCAAR registry 2Health News:New 'real-world' reassuring data from the SCAAR registry 3Health News:For those with diabetes, controlling blood pressure is crucial, but not urgent 2Health News:For those with diabetes, controlling blood pressure is crucial, but not urgent 3Health News:As Nations Develop, So May Bowel Disease 2Health News:Mass prostate cancer screening doesn't reduce deaths 2Health News:Mass prostate cancer screening doesn't reduce deaths 3Health News:Paranoid or Placid? Scans Show Pot's Effect on Brain 2Health News:Paranoid or Placid? Scans Show Pot's Effect on Brain 3
... research model of the Bowman Perfusion Monitor ... continuously in real-time. This precision instrument activates ... which is connected by an umbilical cord ... digital form and send the data to ...
Housed in a small lightweight, flame retardant plastic cases, meters are equipped with a convenient multiposition handle/stand. Measure microcirculation in 1 cubic mm of tissue for real-time assessme...
... featured laser doppler system for continuous ... multiple tissue sites. This latest generation ... Processing (DSP) and laser Doppler flowmetry ... to use, multi-channel monitor, setting new ...
Transcranial vascular DWL doppler....
Medicine Products: